Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. e incidence is from 0.15 to 0.79 cases per 100,000 habitants which present local infiltration of lymph nodes and distant metastasis in 50% of the cases. [6, 22] Clinically, it most commonly presents with a primary lesion, but in 4% of the cases it is absent. [4, 8, 24] In our knowledge, there is only 30 cases of brain metastasis reported in literature. [8] e most common neurological symptoms are linked with elevated intracranial pressure. Brain magnetic resonance imaging (MRI) is the best imaging exam, despite it has unspecific findings.
INTRODUCTION CASE REPORT
A 56-year-old male, Caucasian, with 3-month history of progressive bilateral frontal headache associated with weight loss and dizziness, presented clinical worsening with nausea and confusion periods 2 days before hospitalization.
On admission, the patient presented without pupillary changes or focal signs. e basic biochemical tests were normal, and the MRI showed a cystic/nodular mass effect lesion, with important perilesional edema in the left frontal lobe, with approximately 5 cm, isointense in T1 and T2 sequences. e lesion presented contrast enhancement and restriction of nodular part in the diffusion sense. On spectroscopy, there was high choline/creatine and choline/N-Acetylaspartate ratios suggesting a brain metastasis or glioblastoma [ Figure 1 ].
Due to the important mass effect and size, we opted for the surgical treatment with complete microsurgical resection. e patient evolved with complete neurological improvement, and the biopsy confirms MCC metastasis showing CK20, chromogranin, CD56 positive expressions, and with ki67 of 30% [ Figure 2 ].
A screening to search for other sites of metastases was realized showing liver nodules in CT of the abdomen. e complete skin physical examination was performed without suspect lesions primary lesions. e patient was forwarded to adjuvant treatment using radiotherapy with 50 Gy and chemotherapy. He evolved to death 3 months later due to hepatic complications.
DISCUSSION
MCC is a rare neuroendocrine tumor characterized by small cells with round nuclei, monomorphic, with basophilic nucleus, and cytoplasm minimum associated with high mitosis number and apoptotic bodies. [4, 6, 8, 22, 24] The immunohistochemical is critical to differentiation of the MCC, showing cytokeratins 8, 18, and 20 positives, with sensitivity >90%. The cytokeratin CK20 is mainly used to differentiate lung small-cell carcinoma and was positive in 87% of MCC. The A -chromogranine is present in 52% and enolase in 50% of cases. We can still find somatostatin, neurofilament, CD 56 and synaptophysin positives. [9] Despite its rarity, Hodgson et al. showed in their study that there was an increase in the number of cases in the past decades, from 0.15 to 0.79 cases per 100,000 inhabitants. [4, 11, 22] It typically affects elderly Caucasians with light skin types with a mean age of 69 years, however, can occur in immunosuppressed young people including: organ transplant recipients, HIV-infected individuals, and those with B-cell malignancies, with local recurrence tendencies. Besides the immunodeficiency, other factors such as Merkel cell polyomavirus, ultraviolet radiation exposure appears to contribute to tumor genesis from immature totipotential stem cells. [3, 7, 13, 18] e skin lesion can present rapidly growing, painless, firm, nontender, shiny, flesh-colored or bluish-red, intracutaneous nodule, commonly located in head and neck (29%), upper limbs (24%), lower limbs (21%), stem (8%), and rarely vulva (5%), however, in 4% of cases, it not be found. [17] e Memorial Sloan Kettering Cancer Center in 1999 proposed a size-based grading system and correlated it with survival: Stage I -primary tumor <2 cm; Stage II -primary tumor >2 cm; Stage III -regional disease, and Stage IVdistant disease (metastasis). e survival rates for each stage are for Stage I -81%, Stage II -67%, Stage III -52%, and Stage IV -11% in 5 years. [2, 20] Extracranial metastasis is common in liver, lung, and the skin itself. Intracranial metastasis is uncommon, presenting a little number of cases published in the literature. Feletti et al. reviewed 15 cases showing that the most common sites of metastasis are parietal lobe, cerebellum, and meninges with 3 cases reported for each of these regions. e intracranial involvement can be directly or by the contiguity in case of head lesions. [5, 23] Most common symptoms are the elevation of intracranial pressure, focal signs such as headache, dizziness, vomiting, visual alterations, paresis, parenthesis, and mental confusion. [1, 10, 12] MRI is the best image method to detect the MCC brain metastasis; however, it shows unspecific findings such as hypo/isointense signal in T1 and T2 sequences, with homogeneous enhancing postgadolinium administration. e surrounding edema can be extensive, presenting a bright signal in T2 and flair sequences. [5, 8, 12] e main differential diagnoses of MCC are glioblastoma, brain abscess, and other metastatic tumors. In the case of brain abscess, the surgical findings and a simple histological analysis can differentiate it. Other tissue metastases and glioblastoma need immunohistochemical tests for diagnosis. [9] ere is no official treatment guideline, but according to Harary et al., resection rate is an independent prognostic factor causing benefits such as control of intracranial hypertension and improvement of focal signs caused by mass effect. Other important prognostic factors are burden of disease, age, and adjuvant therapy. [8, 21] e adjuvant treatment options are mainly a role brain radiotherapy with approximately 50 Gy and cytotoxic chemotherapy, but the responses can be nondurable. [8] Actually the immunotherapy with antibodies targeting the programmed cell death protein 1/programmed cell death ligand 1 such as avelumab, pembrolizumab, and nivolumab is an effective option, which is more commonly used in Stage III of disease. [14] [15] [16] 19] In our case, despite complete surgical resection, the patient had a poor prognosis, because he had an advanced disease stage (Stage IV) and a bad response to chemotherapy. We did not use immunotherapy because it was not available in public health system during your assistance.
CONCLUSION
MCC metastasis shows unspecific clinical and radiological findings. It needs to be suspected if the patient has previous compatible skin lesions or history of skin primary MCC. e diagnosis confirmed by immunohistochemical positivity to CK20 and A -chromogranine. e gross total resection seems to provide a survival benefit and should be attempted always as possible if patient clinical condition permits.
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